MedPath

Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache

Not Applicable
Conditions
Chronic Migraine
Medication Overuse Headache
Interventions
Device: Anodal transcranial direct current stimulation
Device: Sham transcranial direct current stimulation
Registration Number
NCT01752439
Lead Sponsor
Dr Armando Perrotta, MD, PhD
Brief Summary

The purpose of the study is to evaluate the efficacy of the transcranial direct current stimulation of the primary motor cortex (M1) in patients affected by refractory chronic migraine (coded as 1.5.1 in the international headache classification 2nd edition, 2004) and medication-overuse headache (coded as 8.1) with migraine as primary headache.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Chronic MIgraine or Medication Overuse Headache according to the diagnostic criteria set out in the 2nd edition of the International Classification of Headache Disorders refractory to treatment according to the Refractory Headache Special Interest Section of the American Headache Society (Schulman et al., 2008)
Exclusion Criteria
  • Other primary or secondary headaches.
  • Any serious systemic or neurological disease or psychiatric disorder.
  • Pregnancy or breastfeeding
  • Previous or current use of other or similar devices for pain control
  • Heart conduction and rhythm disorders
  • Cranial surgery
  • Other pain conditions, accordingly with current guidelines

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Anodal transcranial direct current stimulationAnodal transcranial direct current stimulationAnodal transcranial direct current stimulation
Sham transcranial direct current stimulationSham transcranial direct current stimulationSham transcranial direct current stimulation
Primary Outcome Measures
NameTimeMethod
Change in headache days per monthsat 30, 60 and 90 days after the treatment
Change in drugs intake per monthsat 30, 60 and 90 days after treatment
Secondary Outcome Measures
NameTimeMethod
Change in mean pain intensity score per monthsat 30, 60 and 90 days after treatment
© Copyright 2025. All Rights Reserved by MedPath